

1298004

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 18, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/528,744

FILING DATE: *December 11, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/40595*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



16367 U.S. PTO

PTO/SB/16 (10-01)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 331558680 US

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Enver Richard Peter Gerd		ARSLANTAS SCHMIDT SMITH-JONES RITTER		Konstanz, Germany Konstanz, Germany New York, New York New York, New York	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
TAME BASED CHELATORS AND USES THEREOF					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		24972			
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		15		<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		4		<input checked="" type="checkbox"/> Other: -CHECK FOR FILING FEE	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:					
				500624	
				80.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,

Date December 11, 2003

SIGNATURE

TYPED OR
PRINTED NAME

Norman D. Hanson

TELEPHONE

212-318-3168

REGISTRATION NO.
(if appropriate)

30,946

Docket Number:

LUD 5876 PROV (10314593)

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FOR U.S. LETTERS PATENT

TITLE: TAME BASED CHELATORS AND USES THEREOF

INVENTOR(S): ENVER ARSLANTAS
RICHARD SCHMIDT
PETER SMITH-JONES
GERD RITTER

EXPRESS MAIL


Mailing Label Number EV 331558680 US

Date of Deposit December 11, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee Service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop: Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Fani Malikouzakis

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

Norman Hanson
Reg. No. 30,946
Fulbright & Jaworski L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3168
(212) 318-3400 (fax)

TAME BASED CHELATORS AND USES THEREOF

FIELD OF THE INVENTION

[0001] This invention relates to novel chelating agents, as well as their synthesis and use. The chelators can be used to form complexes with, e.g., metal ions, including heavy metal ions, which can be labelled to give a detectable signal, or otherwise give a detectable signal, such as radioisotopes. Non-radioactive metal ions, i.e., so-called "cold metal" ions, can also be chelated, to form complexes useful in, e.g., MRI work. The chelators can be used to attach these labelled moieties to molecules, such as, but not being limited to, antibodies.

BACKGROUND AND PRIOR ART

[0002] The use of bifunctional chelating agents, such as EDTA, is well known in fields such as medicinal chemistry. They are used, for example, in the diagnosis and treatment of cancer. See, e.g., Sgouros, *Encyclopedia of Cancer, Second Edition*, (Vol. 4, New York, 2002, pp. 29-40).

[0003] To elaborate on the use of these chelators in, e.g., cancer diagnosis and therapy, a chelator combines with and sequesters a therapeutic or diagnostic agent, such as a metal ion, which may be radioactive, and the combination is combined with a molecule that targets a cell, organ, etc., of interest. Examples of such molecules are antibodies of all types (e.g., polyclonal, monoclonal, chimeric, humanized, human, oligomeric, and fragmented antibodies), peptides, or ligands for receptors. For some discussion of relevant molecules, see Heppeler, et al., *Chem. Eur. J.*, 5(7):1974-1981 (1999); Fu, et al., *Eur. J. Org. Chem.*, 3966-3973 (2002). When combined in this way, the agent, e.g., a radio-pharmaceutical, targets, e.g., malignant tissue, and the risk of unspecific radiation, etc., is minimized.

[0004] Ideal chelators have high thermodynamic stability paralleling their chelates, and should also be relatively inert in vivo, to reduce complications caused by loss of the chelate.

[0005] Exemplary of chelators now in use are "DTPA" (diethylenetri aminetetraacetic acid), (Brechtel, et al., *J. Chem. Soc. Perkin Trans.*, 1:1173-1178 (1992)); and DOTA (1,4,7,10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid), and derivatives

like "BAD", described by Kukis, et al., *Canc. Res.*, 55:878-884 (1995). There is always interest, however, in new chelators with improved properties, or different properties, useful in different applications.

[0006] The chelator "TAME," or 1,1,1-Tris-(aminomethyl)ethane, described by Geue, et al., *Aust. J. Chem.*, 36:927-935 (1983), and incorporated by reference, is known as a tridentate ligand, and as a starting material for more complex ligands, as shown by Geue, et al., supra. For example, Green, et al., *J. Am. Chem. Soc.*, 106:3689-3691 (1984) describe salicylaldimines of TAME, as chelating agents for incorporation of gallium ions, such as Ga^{3+} ions. Ga^{3+} , when used with the positron emitting isotope ^{68}Ga , is useful in "positron emission tomography" or "PET." The skilled artisan is very much aware of the usefulness of this technique in medical diagnosis. The chelating agent $H_3[(5-MeOsal)_3tame]$, a TAME derivative, is described by Green, et al., *J. Nucl. Med.*, 26:170-180 (1985), as being useful in assessing myocardial blood flow.

[0007] The structures of the chelators described supra are presented, in figure 4, for ease of reference.

[0008] While Viguier, et al., *Eur. J. Inorg. Chem.*, 2001:1789-1795, incorporated by reference, discloses monofunctional TAME-based polyaminocarboxylic acids, the art does not describe any bifunctional chelating agents, based on TAME, which would be useful for radioimmuno imaging, or therapy. Similarly, there are no reports on TAME based, polyamino polycarboxylic acids.

[0009] It is a purpose of this invention to describe the synthesis of new chelators, based upon the basic TAME structure. This chelators are tripodol, and are bifunctional or monofunctional. When complexed with metal ions, for example, radioisotopes, such as $^{67}Ga^{3+}$ and/or $^{68}Ga^{3+}$, they are useful in the diagnostic and therapeutic modalities discussed supra.

[0010] Various features of the invention are described in the description which follows.

BRIEF DESCRIPTION OF THE FIGURES

[0011] Figure 1 sets forth the scheme for the synthesis of the two chelators described herein. Reference is made in the examples to the numerical identifiers for each compound.

[0012] Figure 2 shows stability studies using ^{67}Ga and the compound depicted by "8" in Figure 1.

[0013] Figure 3 shows stability studies using ^{67}Ga and the compound depicted by "15" in Figure 1.

[0014] Figure 4 shows the structures of the various known chelators discussed herein.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

EXAMPLE 1

[0015] A suspension of pentaerythritol (1.3g, 9.5 mmol), in 15 ml of dry pyridine, was stirred well, and benzoyl chloride (3.6 ml, 31 mmol), was added to it, slowly, at room temperature, with stirring. After 3 hours of stirring, 120 ml of water were added, and the mixture was extracted with 120 ml of ethyl acetate, to yield an organic layer, and an aqueous one.

[0016] The organic layer was washed with a 5% HCl solution (100 ml), and 100 ml of water, dried over MgSO_4 and evaporated. The residue was purified, via flash chromatography, on a silica column using toluene/acetone in a 10:1 ratio. A viscous, colorless oil (1.9 g) resulted (4.3 mmol, 45% yield). $^1\text{H-NMR}$ data (250 MHz, CDCl_3) were $\delta=2.76$ (t, 1H, $^3J = 6.8$ Hz, CH_2OH), 3.68 (d, 2H, $^3J = 6.8$ Hz, CH_2OH), 4.60 (s, 6H, $\text{C}(\text{CH}_2\text{O})_3$), 7.38-8.04 (m, 15H, 3Ph). $\text{C}_{26}\text{H}_{24}\text{O}_7 \cdot \text{H}_2\text{O}$ (466.5), calc.: C 66.94, H 5.62; found: C 66.47, H 5.50.

[0017] The structure of this compound, i.e., Tri-O-benzoyl pentaerythriol, is presented as "1" in figure 1.

[0018] This reaction involved three equivalents of benzoyl chloride for the pentaerythriol, which resulted in a product containing three benzoyl groups, which was easily isolated from over and under benzoylated compounds.

EXAMPLE 2

[0019] The Tri-O-benzoyl-pentaerythriol synthesized in the preceding example was used as a starting material to make Tri-O-benzoyl-O-(4-nitrobenzoyl)-pentaerythriol. To elaborate, 4.25 g of "1" (9.47 mmol), 3 Å molecular sieves (4.0 g), silver oxide (3.3 g, 14.2 mmol), and 4-nitrobenzoyl bromide (67 mg, 0.31 mmol), were combined in 35 ml of dry

CH₂Cl₂, and stirred for forty hours. Following this, the mixture was filtered, and the filtrate was evaporated. Residue was applied to a silica column, and chromatographed, using CH₂Cl₂ as eluent. The result was 4.6 g, 7.88 mmol, 83% yield, of "2" in figure 1. The ¹H-NMR data (250 MHz, CDCl₃), were as follows: δ = 3.77 (s, 2H, CH₂OCH₂Ar), 4.60 (s, 2H, OCH₂Ar), 4.64 (s, 6H, C(CH₂O)₃), 7.37-8.02 (m, 19H Ar, 3 Ph). C₃₃H₂₉NO₉ (583.6) calc.: C 67.92, H 5.01, N 2.40 found: C 67.18, H 5.04, N 2.53.

[0020] In the reaction, supra, silver (I) oxide was used rather than sodium hydride, because sodium hydride generally does not permit O-alkylation with p-nitrobenzyl bromide. See, Fukase, et al., *Tetrahedron Lett.*, 31(3):389-392 (1990).

EXAMPLE 3

[0021] The compound produced supra was acylated. The deacylation, resulting in compound "3" of figure 1, is described herein.

[0022] A mixture of 4.55g (7.8 mmol) of "2" in CH₂Cl₂ (20 ml), MeOH (40 ml), and NaOMe (300 mg, 5.5 mmol) was prepared. The CH₂Cl₂ was added first, and the mixture was well stirred before the other components were added. The mixture was stirred, at room temperature for 24 hours, and then neutralized with an acidic resin, filtered and concentrated under reduced pressure. Residue was crystallized from 40 ml toluene, yielding O-(4-nitrobenzyl) pentaerythriol (1.56g, 5.77 mmol, 74% yield), as a colorless solid. This is "3" in the figure. It had a melting point of 107°C. ¹H-NMR (250 MHz, CDCl₃) are: δ = 2.23 (t, 3H, ³J = 6.7 Hz, CH₂OH), 3.56 (s, 2H, CH₂OCH₂Ar), 3.75 (d, 6H, ³J = 6.7 Hz, C(CH₂OH)₃), 4.6 (s, 2H, OCH₂ Ar), 7.46 (d, 2H, ³J = 8.8 Hz, Ar). C₁₂H₁₂NO₆ (271.3). Calc.: C 53.13, H 5.32, N 5.16. Found: C 53.23, H 5.92, N 4.74. The total yield of "3" over three steps was 28%.

EXAMPLE 4

[0023] This example describes the crucial step of converting three hydroxyl groups in "3" to amine groups, as evidenced by "4" in the figure. To summarize what follows, threefold tosylation of "3," to form "4," followed by nucleophilic substitution of "4" with sodium azide in DMSO, to form 5, and reduction of this triazide to form the triamine of "6," via the Staudinger reaction, accomplished the goal. All numerical references are to figure 1.

[0024] To do this, 3.03g, 11.2 mmol of "3" were dissolved in 90 ml of dry pyridine, followed by addition of 8.60 g, (45.1 nmol) of tosyl chloride, and then 140 mg, (1.15 nmol) of DMAP. This mixture was stirred for 8 hours at room temperature, and then 8 hours at 40°C. The mixture was poured into 250 ml ice water, and extracted with 250 ml CH₂Cl₂, resulting in organic and aqueous layers. The organic layer was washed with 250 ml of water, dried over MgSO₄, and concentrated. Solid residue was purified by treating it with 100 ml of warm MeOH, resulting in compound 4 (8.14 g, 11.1 mmol, 99% yield). The compound was a colorless solid, melting point 134°C. ¹H-NMR (250 MHz, CDCl₃): δ = 2.44 (s, 9H, 3 CH₃ {Tos}), 3.40 (s, 2H, CH₂OCH₂Ar), 4.42 (s, 2H, OCH₂ Ar), 3.94 (s, 6H, C9CH₂O)), 7.30-8.18 (m, 16H, Ar, 3Tos). C₃₃H₃₅NO₁₂S₃ (733.8). calc.: C54.01, H4.94, N 1.61.

[0025] Following this synthesis, compound 4 was converted to 3-azido-2,2-bis (azidomethyl)-1-(4-nitrobenzyloxy) propane, compound "5" in the figure. This was done by forming a solution of "4" (4.96g, 6.76 nmol), in 100 ml of dry DMSO, and then adding 5.3g, or 81 mmol of sodium azide, followed by stirring for 20 hours at 90°C. The mixture was then cooled to room temperature, and poured into 300 ml of cold water. This mixture was then extracted, with ether, in two steps (200 ml and then 100 ml). The organic layer was washed, twice, with brine, and then dried over Na₂SO₄. It was concentrated under reduced pressure to yield 2.03 g, (5.10 mmol, 75% yield) of compound 5, which was a yellowish oil. This could be used without further purification. ¹H-NMR (250 MHz, CDCl₃) data are as follows: δ = 3.39 (s, 6H, C(CH₂O)₃), 3.50 (s, 2H, CH₂OCH₂ Ar), 4.62 (s, 2H, OCH₂ Ar), 7.45-8.24 (m, 4H, Ar).

[0026] The triazide was then converted to a triamine, i.e., 2-(aminoethyl)-2-[(4-nitrobenzyl) oxymethyl]-propane-1,3-diamine, given as "6" in the figure, via the Staudinger reaction. To elaborate, 347 mg, or 0.87 mmol of "5" were dissolved in 5 ml of THF, and then 913 mg (3.5 mmol) of triphenylphosphine, also dissolved in 5 ml of THF, was added to the solution of "5", which was stirred, and ice cold, and was kept under an Ar atmosphere. A total of 2 ml water was added, and the mixture was stirred, at room temperature for 12 hours, followed by six additional hours, at 50°C. The solution was allowed to cool, and was then neutralized by adding concentrated HCl (0.2 ml), after which the mixture was concentrated under reduced pressure. The residue was partitioned between 40 ml of CH₂Cl₂ and 40 ml of 0.5 M HCl, and the aqueous phase was extracted, twice, with 30 ml of CH₂Cl₂ each time. The

aqueous layer was rendered alkaline (i.e., a pH of 9-10), with NaOH, followed by four extractions with 30 ml of CH₂Cl₂ each time. The organic layer was dried over Na₂SO₄, and concentrated, to yield 211 mg (0.66 mmol, 76%), of the triamine of 6, as a colorless oil. This was used in the experiments which follow.

EXAMPLE 5

[0027] All of compound 6 was used in order to add carboxymethyl functionalities, forming compound 7, i.e., tetramethyl 2-[bis(methoxycarbonyl methyl) amino]-2-[(4-nitrobenzyl)(oxymethyl)]-propylene-1,3-dinitrilotetraacetate. While direct alkylation with bromoacetic acid is possible, in theory, the isolation of the resulting, highly polar product, and monitoring the reaction progress are difficult. As a result, a bromoacetic ester is preferred.

[0028] The triamine of 6 was dissolved in 5 ml of dry DMF (211 mg, 0.66 mmol), which had been saturated with Ar. The solution was then alkylated with tert-butyl bromoacetate (0.97 ml, 6.5 mmol), and Na₂CO₃ (687 mg, 6.5 mmol), at 65°C, for 18 hours. The reaction mixture was stirred for 12 hours, at room temperature, and then diluted with 50 ml of ether, and 50 ml of water, to form an organic layer and an aqueous layer.

[0029] The organic layer was washed with 50 ml of brine, then dried over Na₂SO₄, concentrated, subjected to flash chromatography, (petroleum ether / ethyl acetate, 10:1), yielding a hexaalkylated product as a colorless oil (253 mg, 0.27 mmol, 41%). R_f = 0.68 (petroleum ether/acetate, 4:1).

[0030] Better purification resulted, however, when this compound was converted into the hexa(methyl ester) by cleaving the tert butyl ester groups via combining the compound with 3 ml of TFA overnight, followed by methylation of vacuum concentrated residue with diazomethane. Following this, an excess of CH₂N₂, in ether, was added, in a solution of 90% MeOH. After stirring for a few minutes, excess CH₂N₂ was destroyed with acetic acid. The mixture was concentrated *in vacuo*, and residue was purified by flash chromatography (toluene/acetone: 10:1 plus 0.5% Et₃N), yielding compound 7, as a colorless oil (150 mg, 0.21 mmol, 81%). The total yield of compound "7," using three steps, was 32% ¹H-NMR (250 MHz CDCl₃) data: δ = 2.78 (s, 6H, ((CH₂N)₃), 3.52 (s, 2H, 2-H), 3.59 (s, 12H, 6 NCH₂CO₂), 3.67 (s, 18H, 60 Me), 4.49 (s, 2H, OCH₂Ar), 7.47 (d, ³J = 8.7 Hz, 2H, Ar), 8.21

(d, $^3J = 8.7$ Hz, 2H, Ar). MALDI-MS, in positive mode, yielded: m/z : 701.6 [MH^+] calc.: 701.7, 722.6 [MNA^+] (calc.: 723.7), $C_{30}H_{44}N_4O_{15} \cdot 2H_2O$ (736.0) Calc.: C 50.13, H 6.73, N 7.80. Found: C 50.17, H 6.39, N 7.68.

EXAMPLE 6

[0031] The final steps in the production of TAME-Hex A are described herein. A total of 70 mg, (0.10 mmol) of compound 7 was dissolved in MeOH (2 ml), and a solution of NaOH (160 mg, 4.0 mmol) in twice distilled water (1 ml) was added. After stirring for 24 hours, the mixture was acidified with HCl to a pH of about 1.5, and concentrated under reduced pressure. The solid residue was dissolved in a minimum amount of MeOH/H₂O (1:3), loaded onto a RP-18 column and eluted with MeOH/H₂O (1:3 \rightarrow 1:1, + 1% HOAc). Lyophilization of the collected and partially concentrated fractions yielded a fluffy, pale-yellow solid (51 mg, 0.08 mmol, 80%). 1H -NMR (250 MHz), D₂O: δ = 3.36 (s, 6 H, C(CH₂N)₃), 3.74 (s, 12 H, 6 NCH₂CO₂), 3.95 (s, 2 H, 2-H), 4.73 (s, 2 H, OCH₂Ar), 7.62 (d, $^3J = 8.2$ Hz, 2 H, Ar), 8.26 (d, $^3J = 8.2$ Hz, 2 H, Ar). MALDI-MS (positive mode) m/z : 639.5 [MNa^+] (calc.: 639.5). $C_{24}H_{32}N_4O_{15} \cdot H_2O$ (634.6): calc.: C 45.43, H 5.40, N 8.83, found: C 45.43, H 5.71, N 8.81.

[0032] Compound 8 (6.2 mg, 9.8 μ mol) and sodium carbonate (4.3 mg, 40 μ mol) were dissolved in 1.5 ml of water, and added to a suspension of Pd on charcoal (10%, 6 mg) in 1.5 ml of water, which had been previously stirred under a hydrogen atmosphere. After 4.5 hours of hydrogenation under slight pressure (balloon), the mixture was filtered through a pad of celite (which was previously washed with water). Compound 8 will be referred to as "pre-TAME-HexA" hereafter, as it is a more stable form of compound 9, i.e., TAME-HexA. Both compounds 8 and 9 are chelators. Thiophosgene (5 μ l, 25 μ mol) in 3 mL of CHCl₃-layer was separated and the aqueous layer was partially evaporated *in vacuo* (30°C) to remove any volatiles and lyophilized to compound 9 (9.8 mg), as an amorphous, nearly colorless solid. 1H -NMR (250 MHz, D₂O): aromatic protons: δ = 7.31-7.51 ppm (m, 2 H). MALDI-MS (positive mode, ATT-matrix) of a acidified (HCl) sample, m/z : 630.2 [MH^+] (calc.: 629.5), 652.3 [MNa^+] (calc.: 651.5).

EXAMPLE 7

[0033] This example, and the examples which follow, describe the synthesis of a second chelator, referred to as TAME-Hex B.

[0034] The teratosylate of pentaerythriol, described by Fleischer, et al., *J. Org. Chem.*, 36(20):3042-3044 (1971), incorporated by reference and shown as "10" in the figure, was used to make tetrakis-(amino methyl)-methane, described by Riemschneider, et al., *Monatsch. Chem.*, 1965:147-158. This is compound 11 in the figure. This compound, in turn, is reacted with four equivalents of benzaldehyde, followed by reduction of the aldimine, to form compound 12, the triazaadamantane, described by Fleischer, et al., *J. Org. Chem.*, 36(20):3042-3044 (1971). Compound 12 was used to make compound 13, i.e., 2-(amino methyl)-2-[(dibenzylamino)methyl]-propane-1,3-diamine tetrahydrochloride. This was done by stirring a solution of 12 (1.64g, 3.37 mmol), and adding 1.22 ml (7.0 mmol) DIPEA, and 0.7 ml (6.0 mmol) benzyl bromide, at room temperature. This mixture was stirred overnight, resulting in formation of a white suspension. The suspension was diluted, with 80 ml each of ether and toluene, and was then washed with 80 ml of brine & water. This resulted in an organic and aqueous layer. The organic layer was dried over CaCl_2 , and concentrated under reduced pressure. Residue was suspended in ether, filtered, and washed with methanol. The yield was 1.66 g (2.88 mmol, 85%)k, of 7-[(dibenzylamino)methyl]-2,4,6-triphenyl-1,3,5-triazadamantane, as a white powder. The powder was dissolved in freshly distilled THF (40 ml), and 1.5N HCl (50 ml), was added, with vigorous stirring, for 30 minutes. This removed the benzylidene protecting group. THF was removed by rotary evaporation, and the resulting aqueous solution was extracted with CH_2Cl_2 (twice, 50 ml each). The evaporation of the aqueous layer under reduced pressure yielded 1.27 g, 2.77 mmol, 96% yield, of compound 13 (77% yield relative to starting materials).

EXAMPLE 8

[0035] These experiments describe the manufacture of the hexamethyl ester of compound 13, i.e., tetramethyl 2-[bis(methoxycarbonyl methyl)amino]-2-[(dibenzylamino)methyl]-propylene-1,3-dinitrilotetraacetate.

[0036] A total of 1.25 g (2.53 mmol) of compound 13 was dissolved in 15 ml of dry DMF, which was then saturated with Ar. The mixture was then alkylated with 3.2 ml (21

mmol) of tert-butyl bromoacetate, and 2.8 g (26 mmol) Na_2CO_3 , at 65°C , for 8 hours, followed by 12 hours of stirring at room temperature. The mixture was then diluted with 80 ml dichloromethane and 60 ml of water. This resulted in an organic layer and an aqueous layer. The organic layer was washed with 50 ml brine, dried over Na_2SO_4 , concentrated, and subjected to flash chromatography with petroleum ether and ethyl acetate, in a 10:1 ratio. This resulted in the hexylated product as a colorless oil (1.12 g, 1.12 mmol, 44% yield), $R_f = 0.67$, (petroleum ether/ethyl acetate: 4:1).

[0037] In order to improve the purification, the compound described supra was converted into its corresponding, hexa(methyl ester) by cleaving the tert butyl ester groups with TFA (10 ml) with which it was mixed, overnight, followed by vacuum concentrating the residue and methylating with diazomethane. Excess CH_2N_2 , in ether solution was added to a solution of the reactant, in 90% MeOH. Following stirring, excess CH_2N_2 was destroyed with acetic acid. The mixture was then concentrated, *in vacuo*, and the residue was purified by flash chromatography (toluene/acetone: 10:1 plus 1% EtN). Compound 14 resulted, in a yield of 570 mg, 0.77 mmol, 70% as a colorless oil. The ^1H -NMR data (250 MHz, CDCl_3) is as follows: δ - 2.72 (s, 2H, 2-H), 2.90 (s, 6H, $\text{C}(\text{CH}_2\text{N})_3$), 3.59 (s, 16H, $6\text{NCH}_2\text{CO}_2$, $\text{N}(\text{CH}_2\text{Ph})_2$), 3.65 (s, 18H, 60 Me), 7.27-7.34 (m, 10H, 2 Ph), $\text{C}_{37}\text{H}_{52}\text{N}_4\text{O}_{12} \cdot \text{H}_2\text{O}$ (762.9). Calc.: C 58.26, H 7.14, N 7.34. Found: C 58.32, H 7.03, N 7.25.

EXAMPLE 9

[0038] This example describes the final synthesis of TAME-HexB, or 2-[Bis(carboxymethylamino)methyl]-2-[(dibenzylamino)methyl]-propylene-1,3-dinitrilotetraacetic acid, or compound 15 in the figure. A total of 350 mg (0.46 mmol), of compound 14 was dissolved in 5 ml of MeOH, and 6 ml of a solution of NaOH (480 mg, 12.0 mmol, in bidistilled water), was added. This was stirred, for 3 days, after which the mixture was acidified with HCl, to a pH of about 1. The solution was concentrated, under reduced pressure, and the resulting solid residue was dissolved in $\text{MeOH}:\text{H}_2\text{O}$, at a 1:4 ratio, which contained 1% of Et_3N . The solution was loaded onto an RP-18 column, and eluted with $\text{MeOH}:\text{H}_2\text{O}$ (1:4 \rightarrow 10:1, plus 1% HOAc). Lyophilization followed, yielding a colorless solid (171 mg, 0.24 mmol, 52%), containing 1 eq each of HOAc and Et_3N . Crystallization of a portion of this product yielded compound 15, free of HOAc. The ^1H -

NMR data for the compound are as follows: (250 MHz, D₂O: A45*HOAc): δ - 2.07 (s, 3H, OAc), 3.17 (br s, 6H C(CH₂N₃)), 3.41 (br s, 2H, 2-H), 3.54 (br s, 12H, 6NCH₂CO₂), 4.40 (br s, 4H, N(CH₂Ph)₂), 7.53 (br s, 10H, 2 Ph). ¹H-NMR (250 MHz, D₂O, Ph 12): 1.92 (s, 3H, OAc), 2.88 (br s, 2H, 2-H), 2.98 (br s, 6H, C(CH₂N₃)), 3.37 (br s, 12H, 6NCH₂CO₂), 3.70 (br s, 4H, N(CH₂Ph)₂), 7.27-7.48 (m, 10H, 2 Ph) MALDI-MS (positive mode) *m/z*: 661.4 [MH]⁺ (calc.: 660.7), 683.5 [MNa]⁺ (Calc.: 683.7). C₃₁H₄₀N₄O₁₂ (660.7): Calc.: C 56.36, H 6.10, N 8.48, Found: C 56.01, H 6.53, N 8.31.


EXAMPLE 10

[0039] The chelators defined by compounds 8 and 15 in figure 1 and as described, supra, were tested in transchelation experiments, using ¹¹¹In³⁺, and ⁶⁷Ga³⁺, using the known chelator DTPA as a competing ligand. Labelling was carried out using standard methods.

[0040] The results indicated that both chelators were labelled with both isotopes, and less than 0.1% radiometal remained unchelated. With respect to stability, both compounds 8 and 15, when labelled with ¹¹¹In, showed that about 10% of the labelled material was intact after 24 hours.


[0041] Figures 2 and 3 show that the ⁶⁷Ga labelled chelators were even more stable. Labelled TAME-HexA was 94% intact after 10 days, and 99% of the labelled TAME-HexB was stable after the same period of time.

[0042] The foregoing data set forth aspects of the invention, which relate to compounds of formula:



Wherein R_1 is a functional group, such as CN, SCN, O_2N , COOH, SH, a bromoacetamido group or another reactive group, and R_2 through R_7 , which may be the same or different, are H, branched or straight chain alkyl moieties containing from 1 to 10, preferably 1 to 6 carbon atoms, which are preferably straight chained, and which may be substituted by O, N, S, a halide, or other moieties. In particularly preferred embodiments, R_2 - R_7 are the same, and are H, or C_1 - C_6 alkyl, and R_1 is O_2N or SCN. Especially preferred are compounds where R_1 is O_2N , and R_2 - R_7 are the same and are either Me or H, as well as compounds where R_1 is SCN, and R_2 - R_7 are the same and are H.

[0043] A second group of compounds encompassed by the invention are compounds of formula:



Wherein X_1 - X_6 , which may be the same or different, are H or straight chain or branched, substituted or unsubstituted C_1 - C_{10} , preferably straight, unsubstituted, C_1 - C_6 alkyl, X_7 and X_8 , which may be the same or different, are H or a group as defined by R^1 , supra, and Y is H or forms a C=O bond with the carbon atom. In especially preferred embodiments, X_1 - X_6 are the same, and are either methyl or hydrogen.

[0044] The compounds of the invention are useful as chelators which can be used to form complexes with ions, such as metal ions. The ions can be detected with different kinds of techniques. The ions can be detected as they give rise to a detectable signal upon the application of some sort of external field or radiation, e.g. a magnetic field as in magnetic resonance imaging (MRI) or a external radiation field as in x-ray radiation, the chelate/ion complexes then act as contrasting agents. The ions can also be detected by various techniques if the ions are themselves sending out a detectable signal, e.g. if the ions are radioactive isotopes that send out gamma, beta or alpha radiation. Exemplary, but by no means the only types of radioactive ions with which the chelators can form complexes, are ions of gallium, $^{67}\text{Ga}^{3+}$ or $^{68}\text{Ga}^{3+}$, in particular.

[0045] The structure of the chelators permits their attachment to molecules, such as those listed supra, including antibodies, peptides, proteins, ligands, and so forth. The resulting complexes can be used therapeutically or diagnostically, as was elaborated upon supra. The complexes of chelator and target molecule, such as an antibody, is also a feature of this invention, as is the use of these complexes in therapeutic and diagnostic applications.


[0046] Also a feature of the invention are the intermediate compounds 2-13, described herein, as well as the processes for making these, as well as processes for making the compounds described supra.

[0047] Other features of the invention will be clear to the skilled artisan and need not be set forth herein.

[0048] The terms and expression which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expression of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.


WE CLAIM:

1. A compound of formula



- wherein R₁ is a functional group, and R₂-R₇, which may be the same or different, are H, C₁-C₁₀ branched or straight chained, substituted or unsubstituted alkyl.
2. The compound of claim 1, wherein R₁ is CN, SCN, O₂N, COOH, SH, or a bromoacetamido group.
 3. The compound of claim 1, wherein R₂-R₇ are the same.
 4. The compound of claim 3, wherein R₂-R₇ are H.
 5. The compound of claim 4, wherein R₁ is O₂N or SCN.
 6. The compound of claim 4, wherein R₁ is SCN.
 7. The compound of claim 3, wherein R₂-R₇ are methyl.
 8. The compound of claim 7, wherein R₁ is O₂N.
 9. A chelation complex of a metal ion and the compound of claim 1.
 10. A chelation complex of a metal ion and the compound of claim 6.
 11. A chelation complex of a metal ion and the compound of claim 8.

12. The chelation complex of claim 9, 10, or 11, wherein said metal ion is a radioisotope.
13. The chelation complex of claim 12, wherein said radioisotope is $^{67}\text{Ga}^{3+}$.
14. A compound of formula:



Wherein X_1 - X_6 may be the same or different and are H, C_1 - C_{10} , branched or straight chained, substituted or unsubstituted alkyl, X_7 and X_8 may be the same or different and are H, or a functional group, and Y is either H or forms a $C=O$ bond with the carbon to which it is bound.

15. The compound of claim 14, wherein all of X_1 - X_8 and Y are hydrogen.
16. The compound of claim 14, wherein one of X_7 and X_8 is H and the other is CN, SCN, O_2N , $COOH$, SH or a bromacetamido group.
17. The compound of claim 14, wherein X_7 , X_8 and Y are hydrogen, and X_1 - X_6 are methyl.
18. A chelation complex of the compound of claim 14, 15, 16, or 17, and a metal ion.
19. The chelation complex of claim 18, wherein said metal ion is a radioisotope.
20. The chelation complex of claim 18, wherein said radioisotope is $^{67}\text{Ga}^{3+}$.

ABSTRACT OF THE INVENTION

[0049] New bifunctional chelation complexes are described. These are based on the structure of the so-called "TAME-HexA" molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.




Figure 1a




Figure 1b




Figure 2. Stability of ^{67}Ga -8 to transchelation by a 1000 fold excess of DTPA at an ambient temperature.




Figure 3. Stability of ^{67}Ga -15 to transchelation by a 1000 fold excess of DTPA at an ambient temperature.







Figure 4: The structures of BAD, TAME, $H_3[(5-MeOsal)_3tame]$ and TAME-Hex

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/040595

International filing date: 03 December 2004 (03.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/528,744
Filing date: 11 December 2003 (11.12.2003)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse